Stephens initiated coverage on Hologic Inc (NASDAQ:HOLX), citing it as a major player in women’s health, known for its consistent revenue growth, strong free cash flow, and attractive profit margins, is well-positioned in the molecular diagnostics sector post-COVID.
Stephens analyst writes, “Hologic is a leader in women’s health with a portfolio of products that have become the gold standard for care. Hologic emerged from the pandemic with new growth drivers, a scaled installed base, and a stronger balance sheet.”
The analyst says Hologic is well-positioned to execute on near-term targets and fuel long-term growth. A change to cervical cancer screening guidelines can ...